TREATMENT OF ANEMIA IN HEMODIALYSIS-PATIENTS WITH ERYTHROPOIETIN - LONG-TERM EFFECTS ON EXERCISE CAPACITY

被引:0
作者
BARANY, P [1 ]
FREYSCHUSS, U [1 ]
PETTERSSON, E [1 ]
BERGSTROM, J [1 ]
机构
[1] HUDDINGE UNIV HOSP, DEPT CLIN PHYSIOL, S-14186 HUDDINGE, SWEDEN
关键词
ANEMIA; ERYTHROPOIETIN; EXERCISE; HEMODIALYSIS; UREMIA;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
1. The effects of correcting anaemia on exercise capacity were evaluated in 21 haemodialysis patients (aged 39 +/- 12 years) before starting treatment with recombinant human erythropoietin (Hb concentration, 73 +/- 10 g/l; total Hb, 59 +/- 12% of expected), after correction of the anaemia to a Hb concentration of 108 +/- 7 g/l and a total Hb 82 +/- 10% of expected, and in 13 of the patients after 12 months on maintenance recombinant human erythropoietin treatment (Hb concentration 104 +/- 14 g/l, total Hb 79 +/- 17% of expected). Fifteen healthy subjects (aged 41 +/- 9 years), who took no regular exercise, constituted the control group. Maximal exercise capacity was determined on a bicycle ergometer. Oxygen uptake, respiratory quotient, blood lactate concentration, heart rate and blood pressure were measured at rest and at maximal workload. 2. After 6 +/- 3 months on recombinant human erythropoietin, maximal exercise capacity increased from 108 +/- 27 W to 130 +/- 36 W (P<0.001) and the maximal oxygen uptake increased from 1.24 +/- 0.39 litres/min to 1.50 +/- 0.45 litres/min (P<0.001). No significant changes in respiratory quotient (1.16 +/- 0.13 versus 1.18 +/- 0.13) and blood lactate concentration (4.0 +/- 1.8 versus 3.6 +/- 1.1 mmol/1) at maximal workload were observed, but the blood lactate concentration in the patients was significantly lower than that in the control subjects (6.7 +/- 2.3 mmol/l, P<0.01). After the correction of anaemia, the aerobic power was still 38% lower in the patients than in the control subjects and 17% lower than the reference values. 3. After 12 months on maintenance recombinant human erythropoietin treatment (17 +/- 3 months from the start of the study), no further significant changes were observed in maximal exercise capacity (before start, 112 +/- 31 W, 6 +/- 3 months, 134 +/- 42 W, 17 +/- 3 months, 134 +/- 50 W), maximal oxygen uptake (before start, 1.33 +/- 0.45 litres/min; 6 +/- 3 months, 1.59 +/- 0.54 litres/min; 17 +/- 3 months, 1.75 +/- 0.78 litres/min) or blood lactate concentration (before start, 4.4 +/- 1.9 mmol/l; 6 +/- 3 months, 4.0 +/- 1.0 mmol/l; 17 +/- 3 months, 4.7 +/- 2.0 mmol/l). 4. Thus, in haemodialysis patients the improvement in maximal aerobic power after the correction of anaemia persists without marked changes during long-term treatment with recombinant human erythropoietin. We did not observe any effects on exercise capacity that could be attributed to a spontaneous increase in physical activity after treatment of anaemia.
引用
收藏
页码:441 / 447
页数:7
相关论文
共 50 条
  • [21] BLOOD-PRESSURE IN HEMODIALYSIS-PATIENTS DURING AMELIORATION OF ANEMIA WITH ERYTHROPOIETIN
    ABRAHAM, PA
    MACRES, MG
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1991, 2 (04): : 927 - 936
  • [22] Long-Term Effects of Oral L-Carnitine Supplementation on Anemia in Chronic Hemodialysis
    Kudoh, Yasuo
    Aoyama, Shinya
    Toni, Takaaki
    Chen, Qijie
    Nagahara, Daigo
    Sakata, Hiromi
    Nozawa, Akihiko
    [J]. CARDIORENAL MEDICINE, 2014, 4 (01) : 53 - 59
  • [23] HEMODIALYSIS EFFICIENCY AFTER LONG-TERM TREATMENT WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN
    CASATI, S
    CAMPISE, M
    CREPALDI, M
    LOBO, J
    GRAZIANI, G
    PONTICELLI, C
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1989, 4 (08) : 718 - 720
  • [24] CORRECTION OF DEFICIENT PHAGOCYTOSIS DURING ERYTHROPOIETIN TREATMENT IN MAINTENANCE HEMODIALYSIS-PATIENTS
    VEYS, N
    VANHOLDER, R
    RINGOIR, S
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 19 (04) : 358 - 363
  • [25] NUTRITIONAL ASSESSMENT IN ANEMIC HEMODIALYSIS-PATIENTS TREATED WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN
    BARANY, P
    PETTERSON, E
    AHLBERG, M
    HULTMAN, E
    BERGSTROM, J
    [J]. CLINICAL NEPHROLOGY, 1991, 35 (06) : 270 - 279
  • [26] USE OF RECOMBINANT-HUMAN-ERYTHROPOIETIN (RH-EPO) IN THE TREATMENT OF ANEMIA IN HEMODIALYSIS-PATIENTS - A MULTICENTER ITALIAN EXPERIENCE
    BUCCIANTI, G
    COLOMBI, L
    BATTISTEL, V
    [J]. HAEMATOLOGICA, 1993, 78 (02) : 111 - 117
  • [27] Long-term effects of erythropoietin on platelet serotonin storage and platelet aggregation in hemodialysis patients with reference to ketanserin treatment
    Borawski, J
    Rydzewski, A
    Pawlak, K
    Azzadin, A
    Buczko, W
    Mysliwiec, M
    [J]. THROMBOSIS RESEARCH, 1998, 90 (04) : 171 - 180
  • [28] REACTIVITY OF PATIENTS WITH MAINTENANCE HEMODIALYSIS TO ERYTHROPOIETIN IN THE TREATMENT OF RENAL ANEMIA
    Hu, J. P.
    Cheng, X.
    Xu, X. F.
    Yu, G. J.
    Luo, F.
    Zhang, G. S.
    Yang, N.
    Shen, P.
    Yan, X. Y.
    [J]. JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2016, 30 (02) : 535 - 540
  • [29] FIBRINOLYTIC CAPACITY IN HEMODIALYSIS-PATIENTS TREATED WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN
    AUNSHOLT, NA
    AHLBOM, G
    STEFFENSEN, G
    GLUD, T
    [J]. NEPHRON, 1992, 62 (03): : 284 - 288
  • [30] EFFECTS OF HEMODIALYSIS AND LONG-TERM ERYTHROPOIETIN TREATMENT ON PROTEIN-C, AND ON FREE AND TOTAL PROTEIN-S
    CLYNE, N
    EGBERG, N
    LINS, LE
    [J]. THROMBOSIS RESEARCH, 1995, 80 (02) : 161 - 168